Patients with late-onset Pompe disease receiving enzyme replacement therapy (ERT) usually develop IgG antibodies against algucosidase alpha (anti-rhGAA) within the first 3 months. The role of these antibodies in adults is not fully understood. Patel et al. recently published an article entitled: 'The impact of antibodies in late-onset Pompe disease: a case series and literature review', Mol. Genet. Metab. 106 (2012) 301-9 [@bb0005]. They describe three adult Pompe patients with high, sustained antibody titers (HSAT = anti-rhGAA IgG titer \> 1: 51,200 on two or more occasions at or beyond 6 months on ERT) associated with deterioration under ERT.

We analyzed long-term testing for these antibodies performed by Genzyme Corporation using the same methods as described by Patel et al. in 10 genetically confirmed patients with late-onset Pompe disease: None of our patients met the criteria for HSAT.

It is noteworthy that 3/10 patients (P1,8,9) had anti-rhGAA IgG titers that were undetectable or borderline ([Table 1](#t0005){ref-type="table"}). These three patients maintained a stable disease course under ERT. One of those patients with antibodies (P6) developed a sudden increase of the antibody titer to 1:25,600 after 40 months of ERT, which was associated with the need for noninvasive ventilation and walking aids. Nevertheless, in another patient (P2) an antibody titer of 1:25,600 had no impact on the functional status.

In conclusion our data as the data from Patel et al. suggest that peaks of anti-rhGAA IgG antibody titers can occur even after several years of ERT. In our small cohort no clear correlation between anti-rhGAA IgG titer and clinical outcome under ERT can be figured out although those patients without antibodies remained stable under ERT after 4 years compared to deterioration in some patients with antibodies.

The authors thank Genzyme Corporation (Framingham, MA) for performing antibody testing for all patients of this study.

###### 

Demographic and clinical data and anti-rhGAA antibody titers in 10 adult patients with late-onset Pompe disease.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pat. nr.                              Sex   *GAA* genotype              Age at start start of observation (years)   Duration of ERT at start of observation (months)   Start of observation   Comment   Anti-rhGAA antibody titers 4 year observation period   End of observation   Comment                                        
  ------------------------------------- ----- --------------------------- ------------------------------------------- -------------------------------------------------- ---------------------- --------- ------------------------------------------------------ -------------------- ------------ -------- -------- ------- ------- -------------------------------------------
  1                                     M     c.-32-13T\>G\               52                                          53                                                 375                    46        NIV since 2/2005                                       0                    0            0        0        − 15    − 2     --
                                              p.C103G                                                                                                                                                                                                                                                                                

  2                                     M     c.-32-13T\>G\               44                                          43                                                 235                    67        2 crutches                                             6400                 12,800       25,600   12,800   − 95    − 13    --
                                              p.W499R                                                                                                                                                                                                                                                                                

  3                                     F     c.-32-13T\>G\               69                                          35                                                 60                     88        Walking frame                                          3200                 800          3200     3200     − 55    − 16    Wheelchair since 2nd observation year
                                              c.2481 + 102_2646 + 31del                                                                                                                                                                                                                                                              

  4                                     M     c.-32-13T\>G\               43                                          29                                                 387                    32        NIV since 2007                                         6400                 3200         3200     3200     − 37    + 3     --
                                              c.2136_2137del                                                                                                                                                                                                                                                                         

  5                                     F     p.P493L\                    36                                          21                                                 340                    120       --                                                     800                  3200         1600     n.a.     − 60    − 9     --
                                              p.L552P                                                                                                                                                                                                                                                                                

  6                                     F     c.-32-13T\>G\               47                                          27                                                 375                    65        --                                                     n.a.                 1600         25,600   12,800   − 195   − 7     NIV and 1 cane since 3rd observation year
                                              p.L552P                                                                                                                                                                                                                                                                                

  7                                     M     c.-32-13T\>G\               63                                          3                                                  200                    50        1 cane                                                 400                  n.a.         200      200      − 120   − 2     NIV since 3rd observation year
                                              p.G309R                                                                                                                                                                                                                                                                                

  8                                     F     c.-32-13T\>G\               19                                          0                                                  510                    62        --                                                     Pre 0                200          0        0        − 30    − 1     --
                                              c.1438-1G\>C                                                                                                                                                                                                                                                                           

  9[a](#tf0005){ref-type="table-fn"}    F     p.C103G\                    56                                          0                                                  420                    73        --                                                     --                   Pre \< 100   \< 100   \< 100   +/− 0   + 5     --
                                              p.P493L                                                                                                                                                                                                                                                                                

  10[a](#tf0005){ref-type="table-fn"}   M     p.C103G\                    47                                          0                                                  420                    103       --                                                     Pre 0                1600         1600     1600     + 30    +/− 0   --
                                              p.P493L                                                                                                                                                                                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GAA α --- glucosidase; ERT enzyme replacement therapy; 6MWT(m) 6 min walking test in meters; VC vital capacity as % of normal; NIV noninvasive ventilation; n.a. not available.

Patients 9 and 10 are siblings.
